Getting the Price Right: Lessons for Medicare Price Negotiation from Peer Countries Leah Z. RandAaron S. Kesselheim Current Opinion 09 November 2022 Pages: 1131 - 1142
Economic Implications of Endometriosis: A Review Josep DarbàAlicia Marsà Review Article 08 November 2022 Pages: 1143 - 1158
A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid Leukemia Rumjhum AgrawalJoao VieiraRicardo Viana Systematic Review 30 September 2022 Pages: 1159 - 1186
Cost Effectiveness of the First‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting Xinyue DongXiaoning HeJing Wu Original Research Article 08 September 2022 Pages: 1187 - 1205
Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial Edna KeeneySabina SangheraMark S. Clements Original Research Article Open access 06 October 2022 Pages: 1207 - 1220
Conceptual Framework for Optimised Proxy Value Set Selection Through Supra-National Value Set Development for the EQ-5D Instruments Agata ŁaszewskaAyesha SajjadLeona Hakkaart-van Roijen Original Research Article Open access 06 October 2022 Pages: 1221 - 1234
Efficiency of the EmERGE Pathway of Care in Five European HIV Centres Eduard J. BeckSundhiya Mandaliathe EmERGE Consortium Original Research Article 13 October 2022 Pages: 1235 - 1246
Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer’s Perspective Tingting QuShujing ZhangPeter C. Enzinger Original Research Article 15 October 2022 Pages: 1247 - 1259
Comment on “An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia” Bhaskar RegeJames McGroryDavid McDonnell Letter to the Editor Open access 11 November 2022 Pages: 1261 - 1263
Response to Comment on “An Integrated Pharmacokinetic-Pharmacodynamic-Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia” Marjanne A. PienaNatalie HouwingCraig Bennison Letter to the Editor Open access 11 November 2022 Pages: 1265 - 1267
